That's interesting, Alan, because the company doesn't do much talking. Just a lot of doing.
I hope you are right about an interesting week. Could use one. Valuation is high in my opinion, but that's how markets work. They go high; they go low. Opinions and interpretations don't always align with yours.
MassRoots has negative working capital, about 1/3 the sales of HLIX, and about 1/6 the market cap. Would you agree? I think HLIX is at least 6 times more interesting, probably 10 times better managed, and surely offers 10 times the promise. And yet, HLIX does a whole lot less talking and a whole lot more doing.
However, in my *opinion*, both are pretty expensive and definitely not trading at a discount or where I would call a "margin of safety." According to my understanding which is where we agree. Although, I feel confident I'd have a higher valuation than yours. But there is nothing wrong with that. That's why they call it a market. Projections, interpretations, capitalism.
"Alleged" misrepresentations with the two market leaders can't be what you are hearing about since they are both quoted in the few "communications" released from the company.
You can't make the case that Cannabase has misrepresented itself, having a long private history. The only thing foggy is a deal with BioTrack, and there isn't much said about it. We shall see, but I have a hunch that you have personal problems to overcome. One, learning how to be wrong gracefully; and two, learning that you had HLIX wrong and jumped to too many conclusions.